在EGFR抑制后的持久性之路
Purva H Rumde1, Timothy F Burns1,2,3
1Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pennsylvania.
Cancer research
|April 15, 2024
概括
在EGFR突变肺癌中,耐药性持久细胞可在向治疗后导致复发. ASCL1通过促进表皮细胞转化为介质酶细胞的转变来推动这种持久性,从而提供了潜在的新治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 剩余的癌细胞,称为耐药性持久细胞 (DTP),可导致药物耐药性和瘤复发后向治疗.
- 在EGFR突变非小细胞肺癌 (NSCLC) 中,DTPs是导致复发的原因,尽管最初对氨酸激酶抑制剂 (TKI) 的反应有所回应.
- 了解DTP的表型可塑性和体内机制至关重要,因为目前的体外研究有限.
研究的目的:
- 为了研究与TKI osimertinib治疗后EGFR突变肺癌中DTP持久性的机制.
- 在体内识别关键的分子驱动因素和与DTP相关的转录程序.
主要方法:
- 使用EGFR突变肺癌患者衍生的异种移植模型,用osimertinib治疗.
- 采用批量和单细胞RNA测序来分析最大治疗响应时的DTP.
主要成果:
- 鉴定了一种通过转录因子ASCL1.1调解的DTP转录集群.
- 发现ASCL1的过度表达在体外增加了奥西默蒂尼布的耐受性,并触发了表皮细胞转移到介质细胞转移 (EMT) 的转录程序.
- ASCL1诱导持久性的能力取决于上下文,只发生在表观遗传允许的细胞中.
结论:
- ASCL1在与 osimertinib 治疗的EGFR突变性NSCLC中调解DTP异质性和持续性方面发挥着重要作用.
- 这些发现突出了ASCL1作为克服耐药性和预防瘤复发的潜在治疗点.
- 该研究提供了对DTP机制上下文依赖性质的见解,特别是与表观遗传宽容性相关.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.0K
08:52Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
4.0K
相关概念视频
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
